Introspect believes that high-quality digital combination therapies will increase the safety and effectiveness of many mental health drugs. Digital therapeutics (DTx) will provide personalized and scalable treatment to those who might not otherwise be able to access high-quality psychological care.
Program
Lead Indication
Affiliate Company1
RL-007 / Compound2
Cognitive Impairment Associated With Schizophrenia
Recognify Life Sciences
GRX-917 / Deuterated etifoxine
Generalized Anxiety Disorder
GABA Therapeutics
VLS-01 / DMT
Treatment-Resistant Depression
Viridia Life Sciences
DMX-1002 / Ibogaine
Opioid Use Disorder
DemeRx IB
EMP-01 / MDMA derivative
Post-Traumatic Stress Disorder
EmpathBio
LIMITED TO EQUITY INTEREST
COMP360 / Psilocybin3
Treatment-Resistant Depression
COMPASS Pathways
Phase 3
COMP360 / Psilocybin3
Post-Traumatic Stress Disorder
COMPASS Pathways
Phase 2
COMP360 / Psilocybin3
Anorexia Nervosa
COMPASS Pathways
Phase 2
Note: DMT = N,N-dimethyltryptamine; MDMA = 3,4-Methylenedioxymethamphetamine
(1) Perception, Recognify, and DemeRx IB are all variable interest entities; GABA is a non-consolidated VIE with operational involvement through MSA model; EmpathBio and Viridia are wholly-owned subsidiaries; COMPASS Pathways is a non-controlling equity interests
(2) RL-007 compound is (2R, 3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one(L)-(+) tartrate salts
(3) Developing COMP360, a formulation of psilocybin, administered with psychological support from specially trained therapists
Our Technologies
Psilocybin, ibogaine, and many other psychedelic substances have yielded remarkable early signals of their efficacy in treating everything from depression to various forms of addiction. And while Dr. Srinivas Rao, Chief Executive Officer of EntheogeniX Biosciences, shares the cautious optimism of many researchers, he’s careful to point out that these and other substances come with two significant obstacles…
LEARN MORE
InnarisBio specialized in drug formulation bringing its sol-gel based, intranasal excipient technology to atai. The novel technology may enable new drug formulations with unique and optimized modes of delivery across various active ingredients in the atai pipeline, as well as potential assets in the future.
LEARN MORE
PsyProtix is taking a precision psychiatry approach to develop metabolomics-based biomarkers to stratify patients with treatment-resistant depression (TRD) and other mental health indications. By identifying patient subsets with unique metabolic profiles, PsyProtix will test mechanism-based treatments with the goal of improving overall outcomes.
LEARN MORE
JOIN THE ATAI #INSIGHTNETWORK
Receive the latest news on atai and innovations in the space.
Email